GlycoMimetics (GLYC) Reports In-Line Q4 EPS, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. BA
7. SPY
8. INTC
9. JBLU
10. HOOD

Go back to GlycoMimetics (GLYC) Reports In-Line Q4 EPS, Revenues Miss

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020

March 2, 2021 7:30 AM EST

Second half of 2021 remains the target for completion of enrollment of the GlycoMimetics-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML) Enrollment in 2021 is expected to support a planned interim analysis based on event-free survival in the National Cancer Institutes (NCI) registration trial evaluating uproleselan in newly diagnosed AML patients over the age of 60 years and fit for chemotherapy The Company announces plans to take GMI-1687 forward toward an investigational new drug (IND) filing, with acute treatment of acute vaso-occlusive crisis (VOC) in outpatient... More